MENU
JUL 29 - 30 2020

Immuno-Oncology & Cancer Biology Virtual Conference

Advancing Together: Accelerating Discovery through Live Cell Analysis with Agilent, BioTek, and ACEA Biosciences

The rapid development of immuno-oncology therapies has transformed the cancer treatment landscape. Discovering safe, potent, and persistent immune cell products requires a complete understanding of cancer biology and immune cell properties such as activation, cell fate, cytotoxic killing, immunomodulation, and memory. With our real-time live cell analysis tools, gain deeper insights into immune cell function and its response to the immunosuppressive tumor microenvironment.

In addition, our understanding of cancer biology and the development of new drugs is steadily improving through the use of more complex in vitro cancer models that enhance the physiological relevance of assay data. 3D cell culture technologies, particularly those that form spheroid and organoid models, are at the forefront of these measures. Long-term live cell imaging is particularly useful in quantifying drug effects on these complex models.

This live virtual event will feature presentations by leading scientists from several notable institutions. Agilent, and the newest members of the Agilent family, BioTek and ACEA, will be showcasing their latest innovations in cell analysis, including product launches, software demos, and scientific posters. You will also be able to live chat with product experts from all three companies.

 

Register to learn more about these solutions for immuno-oncology and cancer biology applications:

  • Elucidate cell health, behavior, and function with the xCELLigence RTCA eSight’s dual live cell imaging and real-time impedance capabilities

  • Evaluate immune cell function with the new 5-laser, 30 color Novocyte Penteon benchtop flow cytometer

  • Target the source of cancer cell proliferation and survival in the tumor microenvironment with functional, live-cell metabolism using the new Seahorse XF HS Mini Analyzer

  • Discover cell programming to mount a sustained and robust antitumor response with real-time metabolic analysis which enables you to measure and tune the drivers of immune cell fate and function with Seahorse XF technology

  • Conduct detailed quantitative analysis of 3D cell culture systems—including complex immuno-oncology models—using kinetic imaging and powerful image analysis tools available with the BioSpa Live Cell Analysis System and Gen5™ software

  • Utilize efficient and robust microplate reader-based assays with the Cytation™ Cell Imaging Multi-Mode Reader to characterize cellular behavior using both 2D and 3D formats

  • Improve sample quality and assay reproducibility using MultiFlo™ FX Multi-Mode Dispenser optimized for long-term maintenance of biologically relevant 3D cancer model systems

 

For Research Use Only. Not for use in diagnostic procedures.


Speakers
  • Research Fellow, Post-doctoral research Associa, Centre for Regenerative Medicine, University of Edinburgh
  • Senior Field Application Scientist, Agilent Technologies
  • David W. Cugell Professor of Medicine, Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago
  • Member (Professor), Robert G. Webster Endowed Chair, Department of Immunology, St. Jude Children's Research Hospital
  • Senior Principal Scientist, BioTek Instruments
  • Assistant Member, St. Jude Children's Research Hospital
  • Associate Vice President, Agilent Cell Analysis
  • Associate Professor, Department of Fundamental Oncology, University of Lausanne, Associate member, Ludwig Institute for Cancer Research
  • Asst. Professor, Dept. of Pharmacology and Therapeutics, University of Manitoba; Senior Scientist, Research Institute in Oncology and Hematology, CancerCare Manitoba, Canada
  • Field Applications Scientist, BioTek Instruments
  • Associate Professor, Department of Biochemistry & Medical Genetics, University of Manitoba and Senior Scientist, Research Institute in Oncology & Hematology, CancerCare Manitoba
  • Analytical Development Scientist, Cell and Gene Therapy Catapult
  • Professor (Chair of Biochemistry), Trinity College Dublin
  • Scientist, Oncology Discovery, AstraZeneca, Oncology R&D
  • Field Applications Scientist, BioTek Instruments
  • Institute Research Scientist, MD Anderson Cancer Center

Show Resources
You May Also Like
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
NOV 10, 2020
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 10, 2020
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Please join us for this FREE workshop, as we present Agilent’s LC/MS hardware and software solutions for getting the most out of your analysis data....
NOV 11, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 11, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Twelveyears ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event will again bring together clinician...
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 7 th Ann...
NOV 10, 2020 8:00 AM EST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 10, 2020 8:00 AM EST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Join us for presentations by scientists from leading labs in immuno-oncology, drug discovery, cell line development, and 3D/PDO models. Learn how to conduct modern cell-based assays with var...
FEB 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
FEB 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce the 10th annual Laboratory Animal Science (LAS) Virtual Conference which will take place on February 10th 2021. This is the premier on...
Agenda

Scientific posters available for viewing and downloading in the Poster Hall!

*Special Announcement regarding Agilent Flow Cytometry systems – 11am EDT

  • Enabling 3D T-Cell, Tumoroid Invasion, and Organoid Assays Through the Incorporation of Live Cellular Imaging
    JUL 29, 2020 5:00 PM EDT
    Enabling 3D T-Cell, Tumoroid Invasion, and Organoid Assays Through the Incorporation of Live Cellular Imaging
    Brad Larson
    Field Applications Scientist, BioTek Instruments
  • Measuring Immune Cell Killing Dynamics through Real Time Impedance and Live Cell Imaging
    JUL 29, 2020 4:00 PM EDT
    Measuring Immune Cell Killing Dynamics through Real Time Impedance and Live Cell Imaging
    Fabio Cerignoli, PhD
    Senior Field Application Scientist, Agilent Technologies
  • Advances and trends enabling the growth of immune-based cancer research and therapeutics
    JUL 29, 2020 3:00 PM EDT
    Advances and trends enabling the growth of immune-based cancer research and therapeutics
    David Ferrick, PhD
    Associate Vice President, Agilent Cell Analysis
  • Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR.CD28ζ T cells
    JUL 29, 2020 2:00 PM EDT
    Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR.CD28ζ T cells
    Christopher DeRenzo, MD
    Assistant Member, St. Jude Children's Research Hospital
  • Using quantitative imaging microscopy to explore and target the molecular origins of cancer
    JUL 29, 2020 1:00 PM EDT
    Using quantitative imaging microscopy to explore and target the molecular origins of cancer
    Kirk McManus, PhD
    Associate Professor, Department of Biochemistry & Medical Genetics, University of Manitoba and Senior Scientist, Research Institute in Oncology & Hematology, CancerCare Manitoba
  • Linking Cancer Metabolism to Neurodegeneration
    JUL 29, 2020 12:00 PM EDT
    Linking Cancer Metabolism to Neurodegeneration
    Navdeep S. Chandel PhD
    David W. Cugell Professor of Medicine, Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago
  • STAT3 phosphorylation during phagocytosis is required to activate autophagy and prevent macrophage immuno-senescence
    JUL 29, 2020 11:00 AM EDT
    STAT3 phosphorylation during phagocytosis is required to activate autophagy and prevent macrophage immuno-senescence
    Lara Campana, PhD
    Research Fellow, Post-doctoral research Associa, Centre for Regenerative Medicine, University of Edinburgh
  • Metabolic control of T cell tolerance and antitumor immunity
    JUL 29, 2020 10:00 AM EDT
    Metabolic control of T cell tolerance and antitumor immunity
    Hongbo Chi, PhD
    Member (Professor), Robert G. Webster Endowed Chair, Department of Immunology, St. Jude Children's Research Hospital
  • Impedance-based assay to evaluate potency of immunotherapy products
    JUL 29, 2020 9:00 AM EDT
    Impedance-based assay to evaluate potency of immunotherapy products
    Juan Miguel Sanchez Nieto, PhD
    Analytical Development Scientist, Cell and Gene Therapy Catapult
  • High-throughput DNA damage analyses identify synergistic drug combinations to treat malignant brain tumours
    JUL 29, 2020 8:00 AM EDT
    High-throughput DNA damage analyses identify synergistic drug combinations to treat malignant brain tumours
    Sachin Katyal, PhD
    Asst. Professor, Dept. of Pharmacology and Therapeutics, University of Manitoba; Senior Scientist, Research Institute in Oncology and Hematology, CancerCare Manitoba, Canada
  • What intratumoral Tregs eat makes them strong, but vulnerable: a new metabolic intervention for cancer immunotherapy
    JUL 29, 2020 7:00 AM EDT
    What intratumoral Tregs eat makes them strong, but vulnerable: a new metabolic intervention for cancer immunotherapy
    Ping-Chih Ho, PhD
    Associate Professor, Department of Fundamental Oncology, University of Lausanne, Associate member, Ludwig Institute for Cancer Research
  • 3D Culture Methods and Imaging Considerations
    Brad Larson
    Field Applications Scientist, BioTek Instruments
    Valerie Sodi, PhD
    Field Applications Scientist, BioTek Instruments
  • Automated Media Exchange for Long Term Spheroid Assays Using MultiFlo FX's new AMX Module
    Automated Media Exchange for Long Term Spheroid Assays Using MultiFlo FX's new AMX Module
    Brad Larson
    Field Applications Scientist, BioTek Instruments
  • How intracellular metabolic change governs immunity and inflammation
    How intracellular metabolic change governs immunity and inflammation
    Luke O'Neill, PhD
    Professor (Chair of Biochemistry), Trinity College Dublin
  • Modeling anti-tumor function of human T cells
    Modeling anti-tumor function of human T cells
    Michael Overstreet, PhD
    Scientist, Oncology Discovery, AstraZeneca, Oncology R&D
  • Phenotypic and MoA Analysis of Anti-Metastatic Molecules using 3D Tumoroid Invasion Assays, Kinetic Ligand Binding, and Cellular Microscopy
    Phenotypic and MoA Analysis of Anti-Metastatic Molecules using 3D Tumoroid Invasion Assays, Kinetic Ligand Binding, and Cellular Microscopy
    Brad Larson
    Field Applications Scientist, BioTek Instruments
  • Therapeutic targeting of metabolic synthetic lethality in cancer research
    Therapeutic targeting of metabolic synthetic lethality in cancer research
    Yuting Sun, PhD
    Institute Research Scientist, MD Anderson Cancer Center
  • Tools and Techniques for Optimizing Cell Proliferation Studies
    Tools and Techniques for Optimizing Cell Proliferation Studies
    Joe Clayton, PhD
    Senior Principal Scientist, BioTek Instruments
Speakers

  • Lara Campana, PhD
    Research Fellow, Post-doctoral research Associa, Centre for Regenerative Medicine, University of Edinburgh
    Biography
      Experienced Postdoctoral Fellow with a demonstrated history of working in the research industry. Lara is a strong research professional with a Doctorate of Philosophy (Ph.D.) in Cellular and Molecular Immunology from The Open University and the Vita-Salute San Raffaele University (Milan, Italy). She started her career studying the role of innate immunity in acute muscle injury and repair, and she participated as collaborator on projects aimed at understanding the role of macrophages in development, tumour and autoimmune diseases. The results of her PhD studies have been published into various peer-reviewed journals, including The Journal of Leukocyte Biology, PlosOne and The Journal of Immunology. She won the prize as best oral communications at the PhD Meeting 2011. She progressed by moving to Edinburgh to analyze the role of phagocytosis in acute and chronic liver disease. The results of her post-doctoral research have been published, either as first author or as collaborators on peer reviewed journals such as The Journal of Immunology, Journal of Hepatology and Nature Communications. Her core expertise is in the development and analysis of cell-based assays for macrophage function; set up and analysis of multiparametric flow cytometry panels; in vivo models of acute and chronic liver disease and of acute and chronic muscle disease; literature meta-analysis in inflammation and tissue repair. Lara has also an extensive experience as public speaker, having presented at various universities, conferences and events, either as selected or invited talk. During her post-doctoral training she participated to the local academic life by teaching in various undergrad courses, and by demonstrating at various public and community engagement projects. She completed her teaching qualification as Fellow of the Higher Education Academy (FHEA) of the UK in 2016, and her application to Member of the Royal Society of Biology was accepted in 2018.
    • Fabio Cerignoli, PhD
      Senior Field Application Scientist, Agilent Technologies
      Biography
        Dr. Cerignoli is covering the role of Senior Field Application Scientist for the xCELLigence RTCA platform at Agilent Technologies, where he is involved in developing new tools and reagents and in validating the xCELLigence technology across multiple cellular models. He received his Ph.D. in Molecular Pathology from the University of Rome "La Sapienza" in Italy and moved to San Diego to study signal transduction and stem cell differentiation at the Sanford Burnham Medical Research Institute. Before joining Agilent Technologies, Dr. Cerignoli worked with other San Diego-based Biotechnology Companies where he was awarded several NIH small business grants to develop new tools to study compound-mediated cardiotoxicity
      • Navdeep S. Chandel PhD
        David W. Cugell Professor of Medicine, Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago
        Biography
          I received a BA in mathematics (1991) followed by a Ph.D. in Cell Physiology (1996) at the University of Chicago with Dr. Paul Schumacker, Then did my post-doctoral fellowship jointly with Dr. Paul Schumacker and Dr. Craig Thompson (1999). I started my lab in 2000 at Northwestern University Feinberg School of Medicine. My lab has made contributions to understanding the function of mitochondria. For decades, the mitochondria have been primarily viewed as biosynthetic and bioenergetic organelles generating metabolites for the production of macromolecules and ATP, respectively. We have elucidated mitochondria have a third distinct role whereby they participate in cellular signaling processes through the release of reactive oxygen species (ROS) and the metabolite L-2hydroxyglutrate (L-2HG). Our work has implicated the necessity of mitochondrial ROS as second messengers for multiple biological processes including hypoxic activation of HIF dependent gene transcription, cellular differentiation, and immune cell activation. We have also identified that mitochondria release the metabolite L-2HG, which increases histone and DNA methylation to control hematopoietic stem cell (HSC) differentiation and regulatory T cell (Treg) function, respectively. Thus, mitochondria serve as signaling organelles. In the field of cancer, our work established that mitochondrial metabolism and ROS is necessary for tumorigenesis in vivo. Previously, the prevailing idea was that increased aerobic glycolysis (i.e. Warburg effect) was the dominant metabolic reprogramming event in cancer cells. This led to our current understanding that both aerobic glycolysis and mitochondrial metabolism are essential for tumor growth. I have also published a book entitled "Navigating Metabolism" (Cold Spring Harbor Press, 2015).
        • Hongbo Chi, PhD
          Member (Professor), Robert G. Webster Endowed Chair, Department of Immunology, St. Jude Children's Research Hospital
          Biography
            Hongbo Chi, Ph.D. received his Ph.D. from the University of Rochester, and his postdoctoral training from Yale University School of Medicine. In 2007, he started his independent research program at St. Jude Children's Research Hospital, where he is currently a member (professor) in the Department of Immunology, and Robert G. Webster Endowed Chair in Immunology. His research focuses on mechanisms of immune signaling and metabolism, in particular how mTOR and other signaling pathways interplay with metabolic programs in T cell fate decisions. His laboratory has discovered the critical importance of mTOR signaling, metabolism and autophagy in the differentiation and function of effector and regulatory T cells, the control of T cell quiescence and antigen-triggered exit from quiescence, and the regulation of autoimmune and infectious diseases and cancer. His research has also contributed to our understanding of the signaling and metabolic pathways in dendritic cell biology and the crosstalk between innate and adaptive immunity. More recently, his laboratory applies systems biology and immunology approaches, such as proteomics, metabolomics, single cell RNA-sequencing (scRNA-Seq), CRISPR screening and integrative network analysis, to reconstruct metabolic signaling circuits and identify new therapeutic targets in cancer and other immune-mediated diseases.
          • Joe Clayton, PhD
            Senior Principal Scientist, BioTek Instruments
          • Christopher DeRenzo, MD
            Assistant Member, St. Jude Children's Research Hospital
            Biography

              Dr. DeRenzo is a pediatric oncologist and joined the Department of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital, where his goal is to develop and translate promising cell therapies from the laboratory into clinical trials for pediatric patients with solid tumors and brain tumors. Prior to joining St. Jude, he performed his general pediatric training at Case Western Reserve University/Rainbow Babies and Children's Hospital, and pediatric hematology/oncology training at Baylor College of Medicine/Texas Children's Cancer and Hematology Centers, where he stayed on as faculty until transitioning to his new position at St. Jude. He grew up in Southern New Jersey, outside of Philadelphia, and never imagined living in Cleveland, Houston, or Memphis, but has enjoyed living in each of these great cities, and getting to know people from diverse parts of the US and all over the world.

            • David Ferrick, PhD
              Associate Vice President, Agilent Cell Analysis
              Biography

                David Ferrick began his career as a University of California professor, then entrepreneur and currently industry executive focused on life sciences tools, drug discovery and diagnostics specifically in the areas of immunology and cancer. He has commercialized many life science products into new and emerging markets based on nascent technologies and advanced several drug screening programs from target identification to preclinical testing. He has authored over 150 peer reviewed publications and 13 patents along with several book chapters. Dr. Ferrick received his Ph.D. in Microbiology and Immunology from Georgetown University in Washington D.C.

              • Ping-Chih Ho, PhD
                Associate Professor, Department of Fundamental Oncology, University of Lausanne, Associate member, Ludwig Institute for Cancer Research
                Biography
                  Ping-Chih Ho is a cancer immunologist with particular research interest in immunometabolism, the tumor microenvironment and viral infection. My ultimate goal is to exploit our findings to better harness our immune system in fight against infection and malignancy. In addition, I also envision to reprogram the tumor microenvironment, reverse immunosuppression and broaden and boost the efficacy of cancer immunotherapy. Ping-Chih Ho grew up in Taiwan and obtained his basic biomedical training, including bachelor degree (Life Science) and master degree (Biochemical Science), at National Taiwan University. He then obtained his PhD in Department of Pharmacology at University of Minnesota. Ping-Chih then did postdoctoral training with Susan Kaech at Yale University, where he demonstrated how cancer cells evade T cell immunosurveillance by depriving infiltrating T cells of glucose, which is consumed in large amounts by malignant cells. In September 2015, he relocated to Switzerland as a tenure-track assistant professor in the Department of Oncology at the University of Lausanne and act as an adjunct scientist at the Ludwig Institute for Cancer Research. Ping-Chih was promoted as a tenured associate professor at the University of Lausanne in August 2019 and promoted to Associate Member at the Ludwig Institute for Cancer Research in January 2020. Png-Chih's research is also supported by University of Lausanne, the European Research Council, the Cancer Research Institute, the Swiss National Science Foundation, the Melanoma Research Alliance, the Swiss Cancer League, Harry J. Lloyd Fund, Anna Fuller Fund, the ISREC foundation. His research is also acknowledged by several international awards, including the EMBO Young Investigator award, MRA-SITC Young Investigator award, CRI CLIP-investigator award, and the Swiss Bridge Award.
                • Sachin Katyal, PhD
                  Asst. Professor, Dept. of Pharmacology and Therapeutics, University of Manitoba; Senior Scientist, Research Institute in Oncology and Hematology, CancerCare Manitoba, Canada
                  Biography

                    Sachin Katyal received his B.Sc. (Biochemistry) from the University of Alberta and received his Ph.D. (Oncology) at the Cross Cancer Institute and the University of Alberta. His post-doctoral training, at St. Jude Children’s Research Hospital, in the area of DNA damage and repair in neurodevelopment and neuro-oncology was done in the lab of Dr. Peter McKinnon; work that led to publications in internationally-renowned journals such as Nature, Nature Neuroscience and EMBO J. In 2013, Dr. Katyal began his independent academic research position at the University of Manitoba and CancerCare Manitoba where he is an Assistant Professor within the Department of Pharmacology and Therapeutics (D-PT) and, a Senior Scientist within the Research Institute of Oncology and Hematology (RIOH). Dr. Katyal’s research is CIHR- and TFRI-funded; he is the recipient of the CIHR Institute of Cancer Research 2014 Early Career Award in Cancer Research, a CIHR New Investigator award and a TFRI New Investigator Award. He serves on several scientific review committees for international academic journals and grant review panels. More recently, Sachin established industrial partnerships, which have facilitated the development of innovative technology and methodology to accelerate his DNA damage repair research program; instrumental for development of his novel high-throughput genotoxicity and drug screening facility to understand and identify new therapies against brain tumours and leukemia. Sachin is also actively involved in trainee development, mentorship and career progression through various University-, National- and International-wide initiatives, courses and workshops.

                  • Brad Larson
                    Field Applications Scientist, BioTek Instruments
                    Biography

                      Brad has been at BioTek Instruments, INC. since 2009, first as a Principal Scientist in the Applications Group and most recently as a Field Scientist in the South Region. Brad’s early roles included optimizing new assay processes on BioTek’s line of automation, liquid handling, microplate detection, and imaging instrumentation, in addition to supporting new product development. Currently his role is supporting academic, biotech, and pharmaceutical researchers across five states. Prior to joining BioTek, he acquired extensive experience serving as an Automated Solutions Scientist and Applications Scientist with multiple reagent providers. During his 25 year career in the Biotech Industry he has worked with numerous automation and detection platforms, as well as a variety of cell models, to optimize 2D and 3D cell culture assays across multiple research fields. His current work has led to publications in Assay and Drug Development Technologies, The Journal of Laboratory Automation, The Journal of Biomolecular Screening, Cells, and Combinatorial Chemistry and High Throughput Screening, among others. Brad has additionally presented his work at numerous international conferences and workshops across the United States, Europe, and Asia.

                    • Kirk McManus, PhD
                      Associate Professor, Department of Biochemistry & Medical Genetics, University of Manitoba and Senior Scientist, Research Institute in Oncology & Hematology, CancerCare Manitoba
                      Biography

                        Dr. Kirk McManus is an Associate Professor in the Department of Biochemistry and Medical Genetics at the University of Manitoba. He is also a Senior Scientist within the Research Institute of Oncology and Hematology (formerly the Manitoba Institute of Cell Biology) housed within CancerCare Manitoba. He received a BSc (1995) and an MSc (1999) from the University of Manitoba and moved to Edmonton, Alberta to conduct his PhD studies (1999) in Oncology under the supervision of Dr. Michael Hendzel. There he studied the regulation and dynamics of post­translational histone modifications and their influence on chromosome segregation. His post­doctoral studies were performed with Dr. Phil Hieter at the Michael Smith Laboratories in Vancouver, BC, where he utilized cross-species approaches to identify genes that regulate chromosome stability and characterize their impact on cancer development. Dr. McManus joined the University of Manitoba in June, 2009, and research team is focused on identifying and characterizing genes that regulate chromosome stability in various cancer contexts including colorectal and ovarian, and exploiting these characteristics to identify novel therapeutic targets. His team currently couples genetics, biochemistry and cellular biology along with innovative digital imaging microscopy to identify the molecular determinants of chromosome instability and exploit this information using synthetic lethal strategies.

                      • Juan Miguel Sanchez Nieto, PhD
                        Analytical Development Scientist, Cell and Gene Therapy Catapult
                        Biography
                          Juan Miguel Sánchez Nieto studied Biotechnology at Francisco de Vitoria University (Madrid, Spain). He moved to London in 2010 where he did an MSc in Molecular Medicine at UCL. Juan Miguel continued his scientific career at Imperial College London, where he completed a PhD in Developmental and Stem Cell Biology. His research was focused on understanding the differential sensitivity to cell death observed at the onset of embryonic stem cell differentiation. He joined Cell and Gene Therapy Catapult´s Industrialisation team in 2017 as an Analytical Development Scientist. Juan Miguel has been involved in the experimental design and execution of multiple projects related to the development of novel analytics for viral vector, stem cell and somatic cell therapies. Juan Miguel has been leading Cell and Gene Therapy Catapult's efforts in the development and qualification of in vitro potency assays for TCR and CAR-T cell-based immunotherapies.
                        • Luke O'Neill, PhD
                          Professor (Chair of Biochemistry), Trinity College Dublin
                        • Michael Overstreet, PhD
                          Scientist, Oncology Discovery, AstraZeneca, Oncology R&D
                        • Valerie Sodi, PhD
                          Field Applications Scientist, BioTek Instruments
                        • Yuting Sun, PhD
                          Institute Research Scientist, MD Anderson Cancer Center
                        About Us

                        Agilent is a global leader in life science, diagnostics, and analytical laboratory technologies. Now growing in the cell analysis space, Agilent instruments, software, services, solutions, and people provide trusted answers to our customers' most challenging questions.

                        What started as a unique offering of solutions focused on understanding cellular functionality based on underlying metabolic programming has transformed into a market-leading set of innovative tools with the additions of ACEA Biosciences and BioTek Instruments – providing customers the tools they need to uncover unique cell biology, discover novel drug targets, improve preclinical in vitro toxicology, and pioneer the next generation of immunotherapies.

                        Explore a breadth of solutions in real-time, impedance-based analysis of cell function, real-time cell metabolism, cell imaging and microscopy, microplate readers, microplate washers, flow cytometers, and more.

                         

                        For Research Use Only. Not for use in diagnostic procedures.

                        C.E. Credits

                        The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                        Help

                        General LabRoots Questions

                        email support@labroots.com  

                        Virtual Events and Webinars

                        Supported Configurations

                        • Operating System Internet Explorer Firefox Chrome Safari
                          Vista IE8+ FF10+ Chrome15+
                          Windows 7 IE8+ FF10+ Chrome15+
                          Windows 8 IE10 FF10+ Chrome15+
                          Mac OS X   FF10+ Chrome15+ Safari5.1+
                        • Cookie settings: session cookies enabled
                        • Browser configuration must have JavaScript enabled
                        • Adobe Flash player 10.2 or later

                        To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                        Internet Connection

                        • A minimum of 100Kbps is recommended for audio-only events
                        • A minimum of 300Kbps is recommended for speaker on-video events

                        Computer Equipment

                        • Screen Resolution: Minimum 1024x768
                        • Video Card: 65,000 colors minimum
                        • Sound card and speakers (or headphones) for hearing webcast in full format
                        • Audio Card: 16-bit minimum
                        • RAM: 512MB of free RAM

                        Firewall Protocol

                        • HTTP on port 80 or HTTPS on port 443
                        • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                        • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                        Work-At-Home Attendees

                        • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                        For A Seamless Experience

                        When using a mobile device, FREE Mobile Apps are available:

                        - For viewing Webinars:

                        - For viewing Virtual Events

                        Attendee Guide

                        • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                        Virtual Event and Webinar Support:

                        Continuing Education (CME/CE) Support

                        Loading Comments...
                        Show Resources
                        Attendees
                        • See more